Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections.
Aztreonam was administered to 226 patients with lower respiratory tract infections--primarily pneumonia (181 patients)--due to gram-negative bacilli. The clinical response rate was 93%, and the microbiologic cure rate was 78%. Most patients received 1-g or 2-g intravenous doses of aztreonam three times daily for at least five days. Ninety-eight of the 226 patients were involved in a randomized comparison of aztreonam with tobramycin; the latter drug was administered to a group of 34 patients. The overall microbiologic cure rates for the two drugs were 86% and 71%, respectively. Aztreonam is effective for the treatment of lower respiratory tract infections due to susceptible gram-negative bacilli.
D001398:Aztreonam / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006090:Gram-Negative Bacteria; D006801:Humans; D011014:Pneumonia / Q000188:drug therapy; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014031:Tobramycin / Q000627:therapeutic use
D001398:Aztreonam; D014031:Tobramycin